Replies to post #179932 on Biotech Values

[genisi]

AGN new DARPin data

The point of today’s presentation, of course, is to rally support among AGN shareholders for opposing the hostile offer from VRX

Here are the arguments:
http://www.allergan.com/assets/pdf/investor_presentation_jun30_2014.pdf

[DewDiligence]

AGN—Almost lost in the shuffle today were FDA approval of Ozurdex for DME and FDA rejection (again) of Semprana for acute migraine. AGN acquired 100% ownership of Semprana (f/k/a Levadex) in the 2013 buyout of partner, MAPP (#msg-83696395).

[DewDiligence]

AGN’s CC slides on new EPS guidance and operational changes to fend off VRX hostile offer (27 pages):

http://www.sec.gov/Archives/edgar/data/850693/000119312514273649/d758653dex992.htm

The updated EPS guidance for 2014-2016 is shown on slide #20:

• 2014: $5.74-5.80 (20-22% growth vs 2013).
• 2015: $8.20-8.40
• 2016: ~$10.00